Carboxypeptidase

American Urological Association Announces 2024 Innovation Nexus Showcase Selections

Retrieved on: 
Wednesday, January 10, 2024
Nexus, Woman, Patient, Fertility, American Urological Association, Trauma, Therapy, Prostate cancer, Artificial intelligence, Bladder cancer, Urology, Showcase, Cystoscopy, Funding of science, FACS, University, Surgery, Incontinence, Carboxypeptidase, Hyperoxaluria, Conference, Urinary tract infection, Information technology, Urethra, Patient safety, AUA, Medical imaging

Baltimore, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to announce the ten companies chosen through a rigorous and highly competitive selection process for the second annual Innovation Nexus Showcase.

Key Points: 
  • Baltimore, Jan. 10, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is pleased to announce the ten companies chosen through a rigorous and highly competitive selection process for the second annual Innovation Nexus Showcase.
  • Innovation Nexus is a long-term commitment by the AUA to sustain a urology incubator to advance discoveries with key stakeholders to benefit urologic patient care.
  • As part of the multi-faceted program, the AUA will host an annual Innovation Nexus Conference, with the second event being held on May 2 in San Antonio, TX, before the AUA Annual Meeting.
  • For more information on the Showcase and to register to attend the May 2 event, please visit: https://auanexus.org/

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 SPOTLIGHT Study of PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Retrieved on: 
Wednesday, April 19, 2023
Research, Neurology, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Science, Oncology, Membrane, Prostate cancer, PET, RH, Radiopharmaceutical, Recurrence, MD, Patient, Division, American Urological Association, NorthShore University HealthSystem, Carboxypeptidase, Safety, Medical imaging, Urology

The results will be presented at the upcoming American Urological Association’s 2023 Annual Meeting (AUA2023), being held in Chicago, Ill., from April 28 to May 1, 2023.

Key Points: 
  • The results will be presented at the upcoming American Urological Association’s 2023 Annual Meeting (AUA2023), being held in Chicago, Ill., from April 28 to May 1, 2023.
  • 18F-rhPSMA-7.3 is an investigational Prostate-Specific Membrane Antigen-targeted radiohybrid (rh) PET imaging agent.
  • 18F-rhPSMA-7.3 Detection Rates in Patients with Recurrence of Prostate Cancer Following Primary Treatment with Radiation Therapy: Results from the SPOTLIGHT study.
  • Brian T. Helfand, MD, Chief of Division of Urology, NorthShore University HealthSystem, Evanston, Ill., on behalf of the SPOTLIGHT Study Group

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study of 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

Retrieved on: 
Thursday, February 9, 2023
Neurology, Radiology, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Other Health, Membrane, Safety, RH, PET, Prostate cancer, Carboxypeptidase, Multimedia, Radiopharmaceutical, ASCO, Medical imaging

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the presentation of additional results from its completed Phase 3 LIGHTHOUSE trial of 18F-rhPSMA-7.3 in newly diagnosed prostate cancer, at the upcoming ASCO GU 2023 Genitourinary Cancers Symposium (ASCO GU).

Key Points: 
  • Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the presentation of additional results from its completed Phase 3 LIGHTHOUSE trial of 18F-rhPSMA-7.3 in newly diagnosed prostate cancer, at the upcoming ASCO GU 2023 Genitourinary Cancers Symposium (ASCO GU).
  • The conference will be held in San Francisco, Calif., from February 16 to 18, 2023.
  • 18F-rhPSMA-7.3 is an investigational Prostate-Specific Membrane Antigen-targeted radiohybrid (rh) PET imaging agent.
  • The now completed LIGHTHOUSE Phase 3 clinical trial ( NCT04186819 ) was a prospective, Phase 3, multi-center, single-arm, imaging study conducted in the United States and Europe to evaluate the safety and diagnostic performance of 18F-rhPSMA-7.3 Positron Emission Tomography (PET) in men with newly diagnosed prostate cancer.

Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update

Retrieved on: 
Tuesday, October 18, 2022
SAN, Sino Biopharmaceutical Limited, U.S. Securities and Exchange Commission, Therapy, SEC, Efficiency, PST, EPB, Prostate cancer, NYSE, Annual report, Patient, PSMA, Program, Workforce, Cancer, Private Securities Litigation Reform Act, HER2, Goal, Immune system, Company, Board, CEO, Safety, ADC, Carboxypeptidase, EST, GLOBE, Clinical trial, Interim, Forward-looking statement, COVID-19, Control, Vaccine, Communications satellite, Pharmaceutical industry, Management

SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced a strategic reprioritization of its pipeline and provided a corporate update. The strategic assessment considered the company’s cash runway, pipeline near term value creation opportunities, and other factors. As part of this strategic update, Ambrx will streamline its organization to improve efficiency and reprioritize its development pipeline to focus on oncology assets with the greatest potential and strong competitive profiles.

Key Points: 
  • As part of this strategic update, Ambrx will streamline its organization to improve efficiency and reprioritize its development pipeline to focus on oncology assets with the greatest potential and strong competitive profiles.
  • Ms. Hermans continued, As a result of todays reprioritization, management expects Ambrx now has sufficient capital to fund operations into 2025.
  • In mid-August 2022, Ambrx announced that it would undertake a strategic review of its clinical development pipeline.
  • Ambrx will host a webcast to discuss the corporate update today, October 18, 2022 at 5:00 p.m. EST / 2:00 p.m. PST.

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer

Retrieved on: 
Thursday, May 5, 2022
Oncology, Health, Radiology, Clinical Trials, Research, Science, Biotechnology, Booth, AUA, MRI, Membrane, Health, Institute of technology, 3D ultrasound, Isotope, Company, Safety, Patient, Carboxypeptidase, RH, Cancer, Molecular imaging, Google Images, Magnetic resonance, Precision medicine, PSA, Radiopharmaceutical, Interventional radiology, Prostate cancer, Technical University of Munich, CEUS, Therapy, Solution, Cardiac catheterization, Man, Magnetic resonance imaging, Recurrence, Acquisition, Nuclear medicine, PET, Medical imaging

Impact of 18F-rhPSMA-7.3 PET on upstaging of patients with prostate cancer recurrence: results from the prospective, Phase 3, multicenter SPOTLIGHT study

Key Points: 
  • Impact of 18F-rhPSMA-7.3 PET on upstaging of patients with prostate cancer recurrence: results from the prospective, Phase 3, multicenter SPOTLIGHT study
    Blue Earth Diagnostics invites participants at AUA2022 to attend the presentation above and to learn more about the Company at Booth 455.
  • Blue Earth Diagnostics has completed two Phase 3 clinical studies evaluating the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in prostate cancer: (SPOTLIGHT, NCT04186845 ), in men with recurrent disease and (LIGHTHOUSE, NCT04186819 ), in men with newly diagnosed prostate cancer.
  • Blue Earth Diagnostics expanding oncology portfolio encompasses a variety of disease states, including prostate cancer and neuro-oncology.
  • Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy.

Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of 18F-rhPSMA-7.3, an Investigational PET Imaging Agent, in Biochemical Recurrence of Prostate Cancer

Retrieved on: 
Tuesday, February 15, 2022
Research, Clinical Trials, Biotechnology, Radiology, Health, General Health, Other Science, Science, Oncology, Patient, PET, Carboxypeptidase, Man, Recurrence, Prostate cancer, DRS, Membrane, Safety, PSA, Radiopharmaceutical, RH, Lymph, Multimedia, Prostatectomy, ASCO, Medical imaging, Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA), Blue Earth Diagnostics, Bracco Imaging, RADIOHYBRID PROSTATE-SPECIFIC MEMBRANE ANTIGEN (RHPSMA), BLUE EARTH DIAGNOSTICS, BRACCO IMAGING

General use: This 18F-rhPSMA-7.3 PET image shows prostate cancer spread beyond the prostate region.

Key Points: 
  • General use: This 18F-rhPSMA-7.3 PET image shows prostate cancer spread beyond the prostate region.
  • Technical use: This 18F-rhPSMA-7.3 PET image shows detection of recurrent prostate cancer in several retroperitoneal lymph nodes, as indicated by the green arrows.
  • Based on the majority read results from the three blinded, independent PET readers, the overall detection rate (DR) of 18F-rhPSMA-7.3 PET in the SPOTLIGHT study was 83% (322/389).
  • The Phase 3 SPOTLIGHT study investigated the diagnostic performance of 18F-rhPSMA-7.3 PET imaging as a potential decision-making aid in assessing suspected biochemical recurrence of the disease.

Blue Earth Diagnostics Highlights Upcoming Presentation of Key Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer

Retrieved on: 
Tuesday, February 1, 2022
Radiology, Pharmaceutical, Health, Oncology, CEUS, Safety, Solution, Prostate cancer, Isotope, Health, MD, Nuclear medicine, 3D ultrasound, Carboxypeptidase, Technology, RH, Man, Magnetic resonance imaging, Winship Cancer Institute, Recurrence, Cancer, Technical University of Munich, Trial of the century, MRI, PSA, Molecular imaging, PET, Institute of technology, Magnetic resonance, Acquisition, Google Images, ASCO, Interventional radiology, Emory University, Multimedia, Cardiac catheterization, Radiopharmaceutical, Membrane, Medical Affairs Bureau, Medical imaging, Patient

The SPOTLIGHT study ( NCT04186845 ) is a Phase 3, multi-center, single-arm imaging study, conducted in the United States and Europe, to evaluate the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy.

Key Points: 
  • The SPOTLIGHT study ( NCT04186845 ) is a Phase 3, multi-center, single-arm imaging study, conducted in the United States and Europe, to evaluate the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy.
  • Blue Earth Diagnostics has two Phase 3 clinical studies evaluating the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in prostate cancer: (SPOTLIGHT, NCT04186845 ), in men with recurrent disease and (LIGHTHOUSE, NCT04186819 ), in men with newly diagnosed prostate cancer.
  • Blue Earth Diagnostics expanding oncology portfolio encompasses a variety of disease states, including prostate cancer and neuro-oncology.
  • Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy.

Epic Sciences Comprehensive Cancer Profiling Platform Shows Compelling Value Of Cell Analysis In Data Presented At ESMO Congress 2021

Retrieved on: 
Saturday, September 18, 2021
PET, Oncology, Carboxypeptidase, PRINCE, CTC, Patient, MD, Epic Sciences, Roswell Park Comprehensive Cancer Center, Biomarker, Prostate cancer, MCRPC, Prostate, Associate, SAN, European Society for Medical Oncology, FDG, ESMO, Neoplasm, Peter MacCallum Cancer Centre, PSMA, Chinese, Medical imaging

SAN DIEGO, Sept. 18, 2021 /PRNewswire/ -- Epic Sciences , Inc.'s (Epic) Comprehensive Cancer ProfilingPlatform continues to deliver compelling cell analysis information in clinical trials as data being presented today at the virtual European Society for Medical Oncology Congress 2021 (ESMO 2021) demonstrate.

Key Points: 
  • SAN DIEGO, Sept. 18, 2021 /PRNewswire/ -- Epic Sciences , Inc.'s (Epic) Comprehensive Cancer ProfilingPlatform continues to deliver compelling cell analysis information in clinical trials as data being presented today at the virtual European Society for Medical Oncology Congress 2021 (ESMO 2021) demonstrate.
  • "Biomarker analysis is ongoing in this and other studies comparing the Epic Sciences PSMA CTC Assay with PSMA and FDG PET imaging, and patient outcomes.
  • The company's Comprehensive Cancer Profiling Platform, leverages proven and proprietary CTC capabilities, and adds ctDNA and immune cell analysis, to provide more complete data for more efficient analysis and clearer insights.
  • Epic Sciences partners with leading pharmaceutical companies and major cancer centers around the world working to improve patient outcomes.

Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T

Retrieved on: 
Tuesday, August 24, 2021
Medicine, GLOBE, Nuclear medicine, Compliance, Positron emission tomography, PET, Food, IND, Carboxypeptidase, PSMA, Patient, Investigational New Drug, Half-life, Prostate cancer, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medical imaging

We are excited about advancing Cu-64 PSMA to the clinical trial stage and advancing Curiums copper-based radiopharmaceutical imaging platform.

Key Points: 
  • We are excited about advancing Cu-64 PSMA to the clinical trial stage and advancing Curiums copper-based radiopharmaceutical imaging platform.
  • The imaging market has broadly adopted our recently approved Cu-64 imaging agent, said Curium Interim CEO, North America, Mike Patterson.
  • If approved, a Cu-64 PSMA imaging agent would bring unique attributes to the prostate cancer imaging market, including easy access to the product, convenience, and flexibility.
  • For more information about this press release, please contact Janet Ryan, media contact for Curium: [email protected] .